doi: 10.1128/AAC.01243-12.
Epub 2012 Oct 22.
Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump
Affiliations
- PMID: 23089757
- PMCID: PMC3535963
- DOI: 10.1128/AAC.01243-12
Item in Clipboard
Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump
Antimicrob Agents Chemother.
2013 Jan.
Abstract
Achromobacter xylosoxidans is an innately multidrug-resistant pathogen which is emerging in cystic fibrosis (CF) patients. We characterized a new resistance-nodulation-cell division (RND)-type multidrug efflux pump, AxyXY-OprZ. This system is responsible for the intrinsic high-level resistance of A. xylosoxidans to aminoglycosides (tobramycin, amikacin, and gentamicin). Furthermore, it can extrude cefepime, carbapenems, some fluoroquinolones, tetracyclines, and erythromycin. Some of the AxyXY-OprZ substrates are major components widely used to treat pulmonary infections in CF patients.
Similar articles
-
Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00290-17. doi: 10.1128/AAC.00290-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28584156 Free PMC article.
-
First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.Antimicrob Agents Chemother. 2011 Oct;55(10):4912-4. doi: 10.1128/AAC.00341-11. Epub 2011 Aug 1. Antimicrob Agents Chemother. 2011. PMID: 21807978 Free PMC article.
-
AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.FEMS Microbiol Lett. 2020 Jul 1;367(14):fnaa109. doi: 10.1093/femsle/fnaa109. FEMS Microbiol Lett. 2020. PMID: 32592387 Free PMC article.
-
Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.Am J Respir Med. 2003;2(4):321-32. doi: 10.1007/BF03256660. Am J Respir Med. 2003. PMID: 14719998 Review.
-
An update on the management of urinary tract infections in the era of antimicrobial resistance.Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055. Epub 2016 Oct 21. Postgrad Med. 2017. PMID: 27712137 Review.
Cited by
-
Achromobacter Infections and Treatment Options.Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01025-20. doi: 10.1128/AAC.01025-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32816734 Free PMC article. Review.
-
13-(2-Methylbenzyl) Berberine Is a More Potent Inhibitor of MexXY-Dependent Aminoglycoside Resistance than Berberine.Antibiotics (Basel). 2019 Nov 6;8(4):212. doi: 10.3390/antibiotics8040212. Antibiotics (Basel). 2019. PMID: 31698691 Free PMC article.
-
Comparative Genomics Reveals Novel Species and Insights into the Biotechnological Potential, Virulence, and Resistance of Alcaligenes.Genes (Basel). 2023 Sep 10;14(9):1783. doi: 10.3390/genes14091783. Genes (Basel). 2023. PMID: 37761923 Free PMC article.
-
Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.Appl Environ Microbiol. 2013 Dec;79(23):7142-9. doi: 10.1128/AEM.02293-13. Epub 2013 Sep 13. Appl Environ Microbiol. 2013. PMID: 24038696 Free PMC article.
-
Genomic characterization of Achromobacter species isolates from chronic and occasional lung infection in cystic fibrosis patients.Microb Genom. 2021 Jul;7(7):000606. doi: 10.1099/mgen.0.000606. Microb Genom. 2021. PMID: 34292148 Free PMC article.
References
-
- Aisenberg G, Rolston KV, Safdar A. 2004. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 101:2134–2140 - PubMed
-
- Tena D, Gonzalez-Praetorius A, Perez-Balsalobre M, Sancho O, Bisquert J. 2008. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand. J. Infect. Dis. 40:84–87 - PubMed
-
- De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. 2007. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J. Cyst. Fibros. 6:75–78 - PubMed
-
- Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. 2009. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:1554–1560 - PubMed
-
- Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J. Cyst. Fibros. 10:466–469 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
